Canada’s Biodextris Builds Biologics Facility
Canadian CDMO Biodextris plans to build a new industrial-scale vaccine and biologics facility in Laval, Quebec. The company said the cGMP biomanufacturing center and its analytical capabilities will be an asset in its development as a world-class CDMO.
“Our company’s biologics development scientist team will be able to support our customers and offer them a range of integrated services and the most advanced technologies, from the initial development phases, through clinical trials, to commercial manufacturing of the product,” said general manager Alain Carrier.
The center will include laboratory space dedicated to bioprocess development and analytical laboratories for development, method validation and quality control of manufactured products, as well as five dedicated cGMP biomanufacturing suites. Larger volume bioreactors (50 to 200 liters) and aseptic filling capacity will also be installed.
Operations are scheduled to start in the summer of 2023 and the company expects to add about 15 new members of staff over the next few years.
Investment costs in the project will amount to Can$25 million. The Quebec government has agreed to loan Can$4 million, while Investissement Québec will lend Can$1.4 million. The Canadian government will also contribute a repayable sum of Can$1 million.
Biodextris was acquired by French company Clean Biologics in May 2021, giving the Montaigu-Vendée group an entry into North America and providing further opportunity for growth in the region.
Author: Elaine Burridge, Freelance Journalist
